BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31747009)

  • 1. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
    Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
    Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
    Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
    Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
    Narita Y; Muragaki Y; Kagawa N; Asai K; Nagane M; Matsuda M; Ueki K; Kuroda J; Date I; Kobayashi H; Kumabe T; Beppu T; Kanamori M; Kasai S; Nishimura Y; Xiong H; Ocampo C; Yamada M; Mishima K
    Cancer Sci; 2021 Dec; 112(12):5020-5033. PubMed ID: 34609773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
    Lassman AB; Pugh SL; Wang TJC; Aldape K; Gan HK; Preusser M; Vogelbaum MA; Sulman EP; Won M; Zhang P; Moazami G; Macsai MS; Gilbert MR; Bain EE; Blot V; Ansell PJ; Samanta S; Kundu MG; Armstrong TS; Wefel JS; Seidel C; de Vos FY; Hsu S; Cardona AF; Lombardi G; Bentsion D; Peterson RA; Gedye C; Bourg V; Wick A; Curran WJ; Mehta MP
    Neuro Oncol; 2023 Feb; 25(2):339-350. PubMed ID: 35849035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
    van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
    Padovan M; Eoli M; Pellerino A; Rizzato S; Caserta C; Simonelli M; Michiara M; Caccese M; Anghileri E; Cerretti G; Rudà R; Zagonel V; Lombardi G
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
    Gan HK; Reardon DA; Lassman AB; Merrell R; van den Bent M; Butowski N; Lwin Z; Wheeler H; Fichtel L; Scott AM; Gomez EJ; Fischer J; Mandich H; Xiong H; Lee HJ; Munasinghe WP; Roberts-Rapp LA; Ansell PJ; Holen KD; Kumthekar P
    Neuro Oncol; 2018 May; 20(6):838-847. PubMed ID: 29077941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
    Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
    Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
    Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER
    J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
    Mittapalli RK; Stodtmann S; Friedel A; Menon RM; Bain E; Mensing S; Xiong H
    J Clin Pharmacol; 2019 Sep; 59(9):1225-1235. PubMed ID: 30990907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
    Marin BM; Porath KA; Jain S; Kim M; Conage-Pough JE; Oh JH; Miller CL; Talele S; Kitange GJ; Tian S; Burgenske DM; Mladek AC; Gupta SK; Decker PA; McMinn MH; Stopka SA; Regan MS; He L; Carlson BL; Bakken K; Burns TC; Parney IF; Giannini C; Agar NYR; Eckel-Passow JE; Cochran JR; Elmquist WF; Vaubel RA; White FM; Sarkaria JN
    Neuro Oncol; 2021 Dec; 23(12):2042-2053. PubMed ID: 34050676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    van den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; de Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
    Neuro Oncol; 2021 Aug; 23(8):1415. PubMed ID: 32609812
    [No Abstract]   [Full Text] [Related]  

  • 15. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
    Hoogstrate Y; Vallentgoed W; Kros JM; de Heer I; de Wit M; Eoli M; Sepulveda JM; Walenkamp AME; Frenel JS; Franceschi E; Clement PM; Weller M; van Royen ME; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; Golfinopoulos V; van den Bent M; French PJ
    Neurooncol Adv; 2020; 2(1):vdz051. PubMed ID: 32642719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Reardon DA; Lassman AB; van den Bent M; Kumthekar P; Merrell R; Scott AM; Fichtel L; Sulman EP; Gomez E; Fischer J; Lee HJ; Munasinghe W; Xiong H; Mandich H; Roberts-Rapp L; Ansell P; Holen KD; Gan HK
    Neuro Oncol; 2017 Jul; 19(7):965-975. PubMed ID: 28039367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
    Vize CJ; Kim SK; Matthews T; Macsai M; Merrell R; Hsu S; Kundu MG; Yoon J; Kennedy E; Pai M; Bain E; Lassman AB; Moazami G
    Ophthalmic Res; 2023; 66(1):1030-1043. PubMed ID: 37257422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
    Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.